EC Number   |
Protein Variants |
Reference  |
|---|
   3.4.17.23 | V581A |
the mutation in the ectodomain has no effect on sACE2 release |
707074 |
| 3.4.17.23 | V604A |
the mutation in the ectodomain has no effect on sACE2 release |
707074 |
| 3.4.17.23 | more |
overexpression of ACE2 favorably affects the pathological process of left ventricular remodeling after myocardial infarction by inhibiting ACE activity, reducing AngII levels and upregulating Ang(1-7) expression |
708649 |
| 3.4.17.23 | more |
generation of triple-transgenic-model mice with brain ACE2 overexpression on a chronically hypertensive, AngII-increased background. The transgenic mice show dramatically decreased baseline spontaneous baroreflex sensitivity and brain ACE2 activity compared with nontransgenic mice, whereas peripheral ACE2 activity/expression remains unaffected |
708683 |
| 3.4.17.23 | more |
ACE2 overexpression leads to markedly increased myocyte volume, assessed in primary rabbit myocytes |
708684 |
| 3.4.17.23 | more |
overexpression of ACE2, by usage of a recombinant adeno-associated virus 6 delivery system, in myocardium of stroke-prone spontaneously hypertensive rats mediates onset of experimental severe cardiac fibrosis |
708684 |
| 3.4.17.23 | more |
construction of several transgenic linages with differential virological and immunological outcome of severe acute respiratory syndrome coronavirus infection in susceptible and resistant transgenic mice expressing human ACE2, overview. Transgenic lineages AC70 and AC22, representing those susceptible and resistant to the lethal SARS-CoV infection, respectively, are both permissive to SARS-CoV infection, causing elevated secretion of many inflammatory mediators within the lungs and brains, viral infection appears to be more intense in AC70 than in AC22 mice, especially in the brain, differential SARS-CoV-induced morbidity and mortality between AC70 and AC22 mice, overview |
709743 |
| 3.4.17.23 | more |
overexpression of ACE 2 might have a protective effect by inhibiting cell growth and vascular endothelial growth factor a production in vitro |
710171 |
| 3.4.17.23 | D206G |
deleterious missense variant |
762786 |
| 3.4.17.23 | D355N |
variant exhibits lower binding to SARS-CoV-2 S protein |
762786 |
